期刊文献+

伴有复杂核型异常的髓系恶性血液病5号染色体异常分析 被引量:1

Aberrations of Chromosome 5 in Myeloid Malignancies with Complex Chromosome Abnormalities
下载PDF
导出
摘要 为了研究伴有复杂核型异常的髓系恶性血液病的5号染色体异常,对68例经常规染色体分析及多重荧光原位杂交技术检测为复杂核型异常的髓系恶性血液病患者(急性髓系白血病22例,慢性髓系白血病32例和骨髓增生异常综合征14例)的染色体核型进行了分析,研究5号染色体异常情况。结果表明:68例标本中复杂核型异常涉及所有染色体,而5号染色体异常发生率较高,为38.2%(26/68),其中急性髓系白血病发生率为45.5%(10/22),慢性髓系白血病为15.6%(5/32),骨髓增生异常综合征为78.6%(11/14)。涉及的染色体异常以非平衡易位多见,其中有11例同时存在5号和17号染色体异常,9例同时存在5号和7号染色体异常。结论:髓系恶性血液病复杂核型异常中5号染色体异常多见,多为不平衡易位;5号染色体存在异常的病例通常同时伴有7号或17号染色体异常。 This study was aimed to investigate the chromosome 5 abnormalities in complex chromosome aberrations (CCAs) in myeloid malignancies, chromosome aberrations of 68 cases of myeloid malignancies with CCAs were analysed. The 68 cases included 22 cases of acute myeloblastic leukemia (AML), 32 cases of chronic myeloid leukemia (CML) and 14 cases of myelodysplastic syndrome (MDS). The results showed that the complex chromosome abnormalities were found in all chromosomes of 68 cases, but the incidence of chromosome 5 abnormatity was higher (38.2%, 26/68), including 45.5% (10/22) in AML, 15.6% (5/32) in CML and 78.6% (11/14) in MDS. The most common aberrations in chromosomoe 5 were umbalanced translocations. The aberrations of chromosome 5 and chromosome 17 were confirmed simultaneously in 11 cases, the aberrations of chromosome 5 and chromosome 7 were confirmed simultaneously in 9 cases. It is concluded that the aberration of chromosome 5 is common in myeloid malignancies, and presents unbalanced translocation. Aberrations of chromosome 5 often accompany with aberrations of chromosome 7 or 17.
出处 《中国实验血液学杂志》 CAS CSCD 2008年第6期1257-1260,共4页 Journal of Experimental Hematology
关键词 髓系恶性血液病 5号染色体异常 复杂染色体异常 myeloid malignancy chromosome 5 aberration complex chromosome abnormality
  • 相关文献

参考文献10

  • 1Nimer SD, Golde DW. The 5q- abnormality. Blood, 1987; 70 : 1705 - 1712
  • 2Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol, 1996; 33:127 - 138
  • 3Van-den-Berghe H, Michaux L. 5q-, twenty-five years later: a synopsis. Cancer Genet Cytogenet, 1997 ;94:1 -7
  • 4Olney HJ, Le-Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol, 2001 ;14:479 -495
  • 5Smith SM, Le-Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood, 2003 ; 102:43 - 52
  • 6ISCN( 1995 ) :An international system for human cytogenetic normen- clature, Milelman Fed ; Basel: Karger, 1995
  • 7Liu TX, Becket MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin ( CTNNA1 ) in myeloid cell transformation. Nat Med, 2007 ; 13:78 -83
  • 8Greenberg P, Cox C, Le-Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997 ; 89 : 2079 - 2088
  • 9Giagounidis AA, Genning U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res, 2006; 12:5 - 10
  • 10Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol, 2001 ; 19 : 1405 -1413

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部